Advancements in Organ Chip Technology Pave the Way for CRISPR Treatments Against Influenza A

October 15, 2025 - 22:45

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that despite seasonally updated vaccines, influenza still leads to significant morbidity and mortality each year. Researchers are now turning to innovative organ chip technology to develop more effective treatments.

This cutting-edge technology mimics human organ systems on a microchip, allowing scientists to study the virus's effects and test potential therapies in a controlled environment. By integrating CRISPR RNA therapies, researchers aim to target the genetic material of the virus directly, which could lead to more precise and effective treatments.

The use of organ chips not only enhances the understanding of viral behavior but also accelerates the development of therapeutics. As the world grapples with the ongoing threat of influenza A, these advancements represent a promising step towards more effective interventions and potentially saving countless lives in the future.